Search

everythinglearnresearchcommunity

for

Search:↓

IL-17 plays a key role in severe hair loss in chronic alopecia areata.

Blocking CD44 can reduce leukocyte migration in autoimmune skin diseases.

CMV infection increases the risk of GvHD after bone marrow transplants.

CD34 is absent in most basal cell carcinoma cells but present in surrounding skin.

Regulatory γδ T cells help protect hair follicles from alopecia areata and promote hair regrowth.

CD34 is crucial for skin tumor development in mice.

Deleting the MAD2L1 gene in mice led to rapid tumor growth despite chromosomal instability.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

SOCS3 treatment can prevent hair loss by stopping harmful immune responses.

In alopecia areata, certain immune cells increase and express a protein linked to immune activation.

CENPV, a new partner of CYLD, helps regulate ciliary acetylated tubulin and is overexpressed in certain skin tumors.

B cells can both help and hinder the body's defense against melanoma.

CS12192 effectively treats alopecia areata with better safety than current options.

The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.

IL-17 and certain immune cells are linked to more severe alopecia areata.

Memory regulatory T cells need IL-7, not IL-2, to stay in peripheral tissues.

CD4 T cells need IFN-γ to cause hair loss in alopecia areata.

Expanded CD8+ T cells are linked to Alopecia Areata and may cause relapse after treatment.

A new genetic mutation in the CDH3 gene causes hair loss and eye problems in young people.

DMBT1 and galectin-3 may help suppress epithelial skin cancer.

Clonally expanded CD8+ T cells cause alopecia areata.

The role of γδT-cells in causing alopecia areata remains unclear.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

Tissue environment greatly affects the unique epigenetic makeup of regulatory T cells, which could impact autoimmune disease treatment.

New findings suggest targeting IL-23 could treat psoriasis, skin cells can adapt to new roles, direct conversion of skin cells to blood cells may aid cell therapy, removing certain tumor cells could boost cancer immunotherapy, and melanoma may have many tumorigenic cells, not just cancer stem cells.

The study suggests that a specific type of immune cell, memory-like NK cells, may increase during active hair loss in Alopecia areata.

Targeting specific T cells may help treat alopecia areata.

Deleting the MAD2L1 gene is tolerated in certain mouse cancer models.

Tislelizumab can cause cutaneous lupus erythematosus.